Olema Pharmaceuticals Inc (NASDAQ: OLMA) is -17.68% lower on its value in year-to-date trading and has touched a low of $3.00 and a high of $17.79 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The OLMA stock was last observed hovering at around $11.63 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $11.55, the stock is -10.87% and -12.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.74 million and changing -0.69% at the moment leaves the stock -2.24% off its SMA200. OLMA registered 217.31% gain for a year compared to 6-month gain of -4.47%. The firm has a 200-day simple moving average (SMA200) of -$3.69.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -16.73% loss in the last 1 month and extending the period to 3 months gives it a -14.57%, and is -0.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.36% over the week and 9.10% over the month.
Olema Pharmaceuticals Inc (OLMA) has around 74 employees, a market worth around $645.76M and $0.00M in sales. Distance from 52-week low is 285.00% and -35.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-37.86%).
Olema Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.53.The EPS is expected to shrink by -8.57% this year
167 institutions hold shares in Olema Pharmaceuticals Inc (OLMA), with institutional investors hold 97.39% of the company’s shares. The shares outstanding are 54.99M, and float is at 48.46M with Short Float at 10.05%. Institutions hold 93.55% of the Float.
The top institutional shareholder in the company is BVF Inc. with over 7.61 million shares valued at $68.73 million. The investor’s holdings represent 18.41% of the OLMA Shares outstanding. As of Jun 29, 2023, the second largest holder is Logos Global Management LP with 3.74 million shares valued at $33.81 million to account for 9.05% of the shares outstanding. The other top investors are Paradigm Biocapital Advisors LP which holds 3.73 million shares representing 9.02% and valued at over $33.69 million, while Cormorant Asset Management, LP holds 7.45% of the shares totaling 3.08 million with a market value of $27.83 million.
Olema Pharmaceuticals Inc (OLMA) Insider Activity
The most recent transaction is an insider sale by Harmon Cyrus, the company’s Director. SEC filings show that Harmon Cyrus sold 25,000 shares of the company’s common stock on Feb 29 ’24 at a price of $12.41 per share for a total of $0.31 million. Following the sale, the insider now owns 0.85 million shares.
Olema Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 01 ’24 that Harmon Cyrus (Director) sold a total of 5,000 shares of the company’s common stock. The trade occurred on Feb 01 ’24 and was made at $15.56 per share for $77800.0. Following the transaction, the insider now directly holds 0.87 million shares of the OLMA stock.
Still, SEC filings show that on Jan 31 ’24, Harmon Cyrus (Director) disposed off 25,000 shares at an average price of $12.23 for $0.31 million. The insider now directly holds 876,283 shares of Olema Pharmaceuticals Inc (OLMA).
